Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Citius Oncology, Inc. (NASDAQ:CTOR), a biotechnology company with a market capitalization of $132.45 million, filed a prospectus supplement to its registration statement on Form S-1 on Monday. The stock has shown significant momentum, gaining over 43% in the past six months, according to InvestingPro data. The company stated this action was taken to keep its registration statement current with its recently filed Quarterly Report on Form 10-Q.
According to the company’s statement in the SEC filing, the original registration statement was declared effective on July 15, 2025. Citius Oncology sold common stock and warrants in a public offering on July 17, 2025. The prospectus supplement is required because Citius Oncology is not yet eligible to incorporate by reference into the Form S-1 registration statement.
The filing was signed by Leonard Mazur, Chairman and Chief Executive Officer. The information is based on a press release statement from Citius Oncology’s SEC filing.
In other recent news, Citius Oncology, Inc. completed a public offering, raising approximately $9 million to support its immunotherapy, LYMPHIR. The offering included over six million shares of common stock and warrants priced at $1.32 per share. Additionally, Citius Oncology expanded its distribution network for LYMPHIR through a new agreement with Cencora, enhancing its reach for the FDA-approved treatment for cutaneous T-cell lymphoma. Cencora will serve as a wholesale distributor, providing specialty distribution services. Meanwhile, Citius Pharmaceuticals (NASDAQ:CTXR), the parent company of Citius Oncology, regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the stock market. Preparations are underway for the commercial launch of LYMPHIR in the second half of 2025, with sufficient inventory produced to meet demand for up to 18 months post-launch. Citius Pharmaceuticals also announced a direct stock offering expected to generate $6 million, with potential additional proceeds from warrants. The funds are earmarked to support LYMPHIR’s commercial launch and other corporate initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.